SG11201909837YA - Methods for treating lung disorders - Google Patents

Methods for treating lung disorders

Info

Publication number
SG11201909837YA
SG11201909837YA SG11201909837YA SG11201909837YA SG 11201909837Y A SG11201909837Y A SG 11201909837YA SG 11201909837Y A SG11201909837Y A SG 11201909837YA SG 11201909837Y A SG11201909837Y A SG 11201909837YA
Authority
SG
Singapore
Prior art keywords
crititech
lawrence
road
international
pct
Prior art date
Application number
Other languages
English (en)
Inventor
Michael Baltezor
Matthew Mcclorey
William Johnston
Gere Dizerega
James Verco
Original Assignee
Crititech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crititech Inc filed Critical Crititech Inc
Publication of SG11201909837YA publication Critical patent/SG11201909837YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11201909837Y 2017-06-14 2018-06-13 Methods for treating lung disorders SG11201909837YA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762519257P 2017-06-14 2017-06-14
US201862628582P 2018-02-09 2018-02-09
US201862653942P 2018-04-06 2018-04-06
US201862678387P 2018-05-31 2018-05-31
PCT/US2018/037219 WO2018231908A1 (en) 2017-06-14 2018-06-13 Methods for treating lung disorders

Publications (1)

Publication Number Publication Date
SG11201909837YA true SG11201909837YA (en) 2019-11-28

Family

ID=62779154

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201909837Y SG11201909837YA (en) 2017-06-14 2018-06-13 Methods for treating lung disorders
SG10201913400QA SG10201913400QA (en) 2017-06-14 2018-06-13 Methods for treating lung disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913400QA SG10201913400QA (en) 2017-06-14 2018-06-13 Methods for treating lung disorders

Country Status (10)

Country Link
US (3) US10398646B2 (ja)
EP (1) EP3615004A1 (ja)
JP (2) JP6840869B2 (ja)
KR (2) KR102303762B1 (ja)
CN (2) CN115919815A (ja)
AU (2) AU2018284247B2 (ja)
BR (1) BR112019022720A2 (ja)
CA (1) CA3063436A1 (ja)
SG (2) SG11201909837YA (ja)
WO (1) WO2018231908A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016197100A1 (en) 2015-06-04 2016-12-08 Crititech, Inc. Nozzle assembly and methods for use
WO2017176628A1 (en) 2016-04-04 2017-10-12 Crititech, Inc. Methods for solid tumor treatment
CA3063420A1 (en) 2017-06-09 2018-12-13 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
CN115919815A (zh) 2017-06-14 2023-04-07 克里蒂泰克公司 治疗肺部疾病的方法
KR20200064112A (ko) 2017-10-03 2020-06-05 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
US20190365698A1 (en) * 2018-05-31 2019-12-05 Crititech, Inc. Use of Antineoplastic Agents to Stimulate the Immune System for Treatment of Cancer
KR20210016511A (ko) * 2018-05-31 2021-02-16 크리티테크, 인크. 입양 세포 요법 및 암 백신을 위한 종양 특이적 면역 세포를 대상체로부터 단리하는 방법
WO2020072090A1 (en) * 2018-10-03 2020-04-09 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for production of tertiary lymphoid structures (tls)

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
JP2001513078A (ja) * 1996-12-30 2001-08-28 バテル・メモリアル・インスティテュート 吸入により新生物を治療する製剤とその方法
PT1023050E (pt) 1997-06-27 2013-12-04 Abraxis Bioscience Llc Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
JP3418751B2 (ja) 1998-01-22 2003-06-23 参天製薬株式会社 フルオロメトロン懸濁型点眼剤
IL131217A0 (en) 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6221153B1 (en) 1998-06-09 2001-04-24 Trevor Percival Castor Method for producing large crystals of complex molecules
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6113795A (en) 1998-11-17 2000-09-05 The University Of Kansas Process and apparatus for size selective separation of micro- and nano-particles
CA2351947C (en) 1998-11-25 2008-10-21 Universitatsklinikum Freiburg Hyperforin as cytostatic agent and hyperforin ointment or cream as application form
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
US7217735B1 (en) 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
NZ516083A (en) 1999-05-27 2003-08-29 Acusphere Inc Porous drug matrices and methods of manufacture thereof
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6616849B1 (en) 1999-08-25 2003-09-09 Shimadzu Corporation Method of and system for continuously processing liquid materials, and the product processed thereby
CA2388844A1 (en) 1999-11-12 2001-05-25 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
KR100799089B1 (ko) 1999-12-04 2008-01-29 리서치 디벨럽먼트 파운데이션 에어로졸화된 약물의 침착 증진 조성물
US6620351B2 (en) 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
US20040033267A1 (en) 2002-03-20 2004-02-19 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US6562952B1 (en) 2000-10-31 2003-05-13 The University Of Kansas Precipitation of proteins from organic solutions
US20020081339A1 (en) 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
US20020192280A1 (en) 2001-05-01 2002-12-19 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
DE60118983T3 (de) 2001-07-02 2016-07-07 Micro & Nano Materials Sagl Verfahren zur Herstellung von Nano- und Mikro-Teilchen
AU2002323266B2 (en) * 2001-08-20 2008-04-24 Transave, Inc. Method for treating lung cancers
US20030054042A1 (en) 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20030134810A1 (en) 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
ES2625340T3 (es) 2001-10-15 2017-07-19 Crititech, Inc. Composiciones y métodos para la administración de fármacos escasamente solubles en agua y métodos de tratamiento
US20030166509A1 (en) 2001-11-20 2003-09-04 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery and methods of use thereof
WO2003075977A2 (en) 2002-03-05 2003-09-18 Cleveland State University Agglomerated particles for aerosol drug delivery
CA2483218C (en) 2002-04-25 2012-07-10 Nektar Therapeutics Uk Ltd Particulate materials
EP1499299A2 (en) 2002-04-26 2005-01-26 Teva Pharmaceutical Industries Ltd. Microparticle pharmaceutical compositions for intratumoral delivery
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
CN1255394C (zh) 2002-06-24 2006-05-10 成都思摩纳米技术有限公司 紫杉醇纳米微粒的制备方法及应用
KR100573289B1 (ko) 2002-07-20 2006-04-24 대화제약 주식회사 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법
CA2504268A1 (en) * 2002-10-30 2004-11-18 Spherics, Inc. Nanoparticulate bioactive agents
KR100508518B1 (ko) 2002-11-13 2005-08-17 한미약품 주식회사 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US7455797B2 (en) 2003-02-28 2008-11-25 Ferro Corporation Method and apparatus for producing particles using supercritical fluid
CN102697737B (zh) 2003-04-03 2014-03-19 杰西.L.-S.奥 负载肿瘤靶向药物的颗粒
US20060147535A1 (en) 2003-04-16 2006-07-06 Poongunran Muthukumaran Methods for and compositions of anticancer medicaments
US20050059613A1 (en) 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
US8021831B2 (en) 2003-08-25 2011-09-20 Board Of Regents, The University Of Texas System Taxane chemosensitivity prediction test
JP2007001865A (ja) 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
AU2004283464B8 (en) 2003-10-15 2011-04-14 Syncore Biotechnology Co., Ltd Method of administering cationic liposomes comprising an active drug
US7208106B2 (en) 2003-10-24 2007-04-24 Ferro Corporation Method of forming particles
CA2544627A1 (en) * 2003-11-05 2005-05-19 Elan Pharma International Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
GB0402963D0 (en) 2004-02-11 2004-03-17 Univ Nottingham Counter current mixing device for two different fluids
US8043631B2 (en) 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
US7833444B2 (en) 2004-10-29 2010-11-16 Nara Machinery Co., Ltd. Fine particle granulation method
WO2006068890A2 (en) 2004-12-14 2006-06-29 Transave, Inc. Lipid particles comprising bioactive agents, methods of preparing and uses thereof
ES2265262B1 (es) 2005-01-31 2008-03-01 Activery Biotech, S.L.(Titular Al 50%) Procedimiento para la obtencion de sistemas micro- y nanodispersos.
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
EP1855659A2 (en) * 2005-02-24 2007-11-21 Elan Pharma International Limited Nanoparticulate formulations of docetaxel and analogues thereof
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
JP5635231B2 (ja) 2005-03-31 2014-12-03 リッズ エービーＬｉｄｄｓ Ａｂ 活性物質の局所送達に基づく前立腺疾患の治療方法
CN1923189A (zh) 2005-08-30 2007-03-07 孔庆忠 一种紫杉碱类抗癌药物的缓释注射剂
CN101291658B (zh) 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
BRPI0619635A2 (pt) 2005-12-11 2011-10-04 Scf Technologies As produção de materiais de tamanho nano
US8906392B2 (en) 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
CN101336899A (zh) 2006-01-25 2009-01-07 济南帅华医药科技有限公司 含紫杉烷的抗癌缓释注射剂
KR101378174B1 (ko) 2006-03-14 2014-03-27 리드스 에이비 생재흡수성의 방출 제어형 조성물
CA2647073A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Drug microparticles
CN101460147A (zh) * 2006-04-03 2009-06-17 特瓦制药工业有限公司 药物微粒
JP4705691B2 (ja) 2006-10-11 2011-06-22 クリティテック・インコーポレイテッド 使用のための容器に小さい医薬粒子を沈殿させるための方法
CA2680106A1 (en) 2007-03-23 2008-10-02 H. William Bosch Gamma radiation sterilized nanoparticulate docetaxel compositions and methods for making the same
TWI405590B (zh) 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
US20100166869A1 (en) * 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
CN101754747A (zh) * 2007-06-05 2010-06-23 Paka肺部医药公司 用于向肺脏递送药物的方法以及组合物
WO2009006590A2 (en) 2007-07-04 2009-01-08 Dr. Reddy's Laboratories Ltd. Docetaxel process and polymorphs
CN101129338A (zh) 2007-08-27 2008-02-27 四川大学 超临界流体新技术微细化抗癌药物紫杉醇
KR20100122510A (ko) 2008-03-06 2010-11-22 닛토덴코 가부시키가이샤 중합체 파클리탁셀 접합체 및 암 치료 방법
CA2737543C (en) 2008-09-19 2015-01-06 Activus Pharma Co., Ltd. Composite organic compound powder for medical use and production method and suspension of the same
JP2012510489A (ja) 2008-12-02 2012-05-10 バイオコンパティブルズ ユーケー リミテッド 膵がんの治療
PT104693B (pt) 2009-07-27 2011-11-24 Univ Lisboa Nanopartículas lipídicas semi-sólidas contendo um agente antineoplásico e seu processo de preparação
SG178885A1 (en) 2009-08-24 2012-04-27 Baylor College Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
US8623329B1 (en) 2009-10-13 2014-01-07 Aerophase, Inc. Method for the treatment of lung tumors
CN102091062A (zh) * 2009-12-11 2011-06-15 国家纳米技术与工程研究院 一种采取吸入给药紫杉醇治疗肺癌的方法
CN101829061A (zh) 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 一种紫杉醇纳米颗粒组合物及其制备方法
EP2575803B1 (en) 2010-06-02 2017-07-26 Abraxis BioScience, LLC Methods of treating bladder cancer
WO2012039602A1 (en) 2010-09-21 2012-03-29 Universiteit Utrecht Holding B.V. Tunable, biodegradable linker molecules for transient conjugation of components in drug delivery systems, and drug delivery systems prepared therewith
WO2012051426A2 (en) 2010-10-15 2012-04-19 Glaxo Group Limited Aggregate nanoparticulate medicament formulations, manufacture and use thereof
WO2012096995A2 (en) 2011-01-11 2012-07-19 Boston Scientific Scimed, Inc. Coated medical devices
ES2629187T3 (es) 2011-04-20 2017-08-07 The University Of Sydney Material en forma de partículas y toxina celular para su uso en el tratamiento de un tumor sólido
WO2013052158A2 (en) 2011-04-26 2013-04-11 William Marsh Rice University Targeted nanovectors and their use for treatment of brain tumors
MX351781B (es) 2011-06-17 2017-10-30 Berg Llc Composiciones farmaceuticas inhalables.
JP6162112B2 (ja) 2011-06-27 2017-07-12 クリスタル・デリバリー・ビー・ブイ 制御された放出システム
FR2980683B1 (fr) * 2011-09-30 2014-11-21 Univ Paris Curie Dispositif de guidage d'un instrument medical insere dans une voie naturelle ou une voie artificielle d'un patient
CN102488682A (zh) 2011-11-22 2012-06-13 四川九章生物化工科技发展有限公司 绿原酸的抗癌新用途
US10555911B2 (en) 2012-05-04 2020-02-11 Yale University Highly penetrative nanocarriers for treatment of CNS disease
TW201408304A (zh) 2012-08-31 2014-03-01 Cathay General Hospital 一種合併抗癌藥物及荷爾蒙之抗腎細胞癌藥物及其製造方法
BR112015006176B1 (pt) 2012-09-21 2023-04-18 Intensity Therapeutics, Inc Uso de um agente terapêutico e de um agente de intensificação de permeação intracelular
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
KR20160148723A (ko) 2013-02-28 2016-12-26 화이자 인코포레이티드 증가된 안정성의 신규한 액체 조성물
US9925512B2 (en) 2013-03-14 2018-03-27 Crititech, Inc. Equipment assembly for and method of processing particles
US8778181B1 (en) * 2013-03-14 2014-07-15 Crititech, Inc. Equipment assembly for and method of processing particles
EP2978420A4 (en) 2013-03-28 2016-12-21 Bbs Nanotechnology Ltd STABLE NANOCOMPOSITION COMPRISING PACLITAXEL, PROCESS FOR ITS PREPARATION, USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US9301926B2 (en) 2013-04-10 2016-04-05 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
WO2015055796A1 (en) 2013-10-16 2015-04-23 Université Libre de Bruxelles Formulations useful in the treatment of proliferative diseases affecting the respiratory tract
BR112016013896A2 (pt) 2013-12-17 2017-10-10 Genentech Inc métodos de tratamento de câncer positivo para her2 usando antagonistas de ligação do eixo de pd-1 e anticorpos anti-her2
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
WO2015103005A1 (en) 2014-01-03 2015-07-09 Research Institute At Nationwide Children's Hospital Amphiphilic amine compounds and their use as therapeutic agents and nanocarriers
TWI601542B (zh) 2014-04-18 2017-10-11 林信湧 一種用於治療肺癌之吸入式醫藥組成物及其備製方法
WO2015187194A1 (en) 2014-06-01 2015-12-10 Crititech, Inc. Use of paclitaxel particles
US11033620B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
WO2016197100A1 (en) * 2015-06-04 2016-12-08 Crititech, Inc. Nozzle assembly and methods for use
WO2017049083A2 (en) 2015-09-16 2017-03-23 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
AU2016326747A1 (en) 2015-09-25 2018-03-01 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
DE202016006620U1 (de) 2015-10-28 2017-04-12 Qass Gmbh Vorrichtungen zum Beobachten eines Magnetfelds eines Materialvolumens
AU2017210031C1 (en) 2016-01-20 2020-11-26 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
WO2017176628A1 (en) 2016-04-04 2017-10-12 Crititech, Inc. Methods for solid tumor treatment
CN107281502B (zh) 2016-04-05 2021-05-04 上海市肿瘤研究所 一种复合显影温敏凝胶栓塞剂、制备方法及其应用
US10894093B2 (en) 2016-04-15 2021-01-19 Cellectis Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3506942B1 (en) 2016-09-01 2022-11-16 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
WO2018170210A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of vulvar intraepithelial neoplasia (vin) and genital warts using nanoparticles of taxanes
WO2018170207A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin keratoses using nanoparticles of taxanes
KR102658256B1 (ko) 2017-03-15 2024-04-16 디에프비 소리아, 엘엘씨 탁산 나노입자를 사용한 피부 악성 종양의 치료용 국소 요법
CA3063420A1 (en) 2017-06-09 2018-12-13 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
CN115919815A (zh) 2017-06-14 2023-04-07 克里蒂泰克公司 治疗肺部疾病的方法

Also Published As

Publication number Publication date
US10398646B2 (en) 2019-09-03
US10507181B2 (en) 2019-12-17
AU2018284247A1 (en) 2019-11-07
US20190314277A1 (en) 2019-10-17
US20180360748A1 (en) 2018-12-20
AU2020204217A1 (en) 2020-07-16
EP3615004A1 (en) 2020-03-04
JP2021075571A (ja) 2021-05-20
JP6840869B2 (ja) 2021-03-10
US20200060969A1 (en) 2020-02-27
KR20200015479A (ko) 2020-02-12
JP2020523286A (ja) 2020-08-06
RU2019134091A (ru) 2021-07-14
CN115919815A (zh) 2023-04-07
SG10201913400QA (en) 2020-03-30
CN110799176A (zh) 2020-02-14
KR102303762B1 (ko) 2021-09-23
BR112019022720A2 (pt) 2020-05-12
RU2019134091A3 (ja) 2021-11-08
US11160754B2 (en) 2021-11-02
KR20210118468A (ko) 2021-09-30
AU2018284247B2 (en) 2020-04-30
WO2018231908A1 (en) 2018-12-20
CA3063436A1 (en) 2018-12-20
AU2020204217B2 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
SG11201909837YA (en) Methods for treating lung disorders
SG11201808125RA (en) Methods for solid tumor treatment
SG11201811432WA (en) Rna for cancer therapy
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201901126UA (en) Combination therapy for cancer
SG11201900028VA (en) Crispr/cas9-based compositions and methods for treating cancer
SG11201808990QA (en) Compositions for topical application of compounds
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201805645QA (en) Lsd1 inhibitors
SG11201808913WA (en) Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
SG11201803906PA (en) Control of cellular redox levels
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201909840TA (en) Treatment of epithelial cysts by intracystic injection of antineoplastic particles
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201804770QA (en) Method and arrangement for recovery of salt
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201809882XA (en) Pharmaceutical combinations for treating cancer